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Abstract: Multiple epidemiological studies identify Dolosigranulum pigrum as a candidate beneficial bac-
terium based on its positive association with health, including negative associations with nasal/nasopha-
ryngeal colonization by the pathogenic species Staphylococcus aureus and Streptococcus pneumoniae
Using a multipronged approach to gain new insights into D. pigrum function, we observed phenotypic
interactions and predictions of genomic capacity that support the idea of a role for microbe-microbe
interactions involving D. pigrum in shaping the composition of human nasal microbiota. We identified
in vivo community-level and in vitro phenotypic cooperation by specific nasal Corynebacterium species.
Also, D. pigrum inhibited S. aureus growth in vitro, whereas robust inhibition of S. pneumoniae required
both D. pigrum and a nasal Corynebacterium together. D. pigrum l-lactic acid production was insuf-
ficient to account for these inhibitions. Genomic analysis of 11 strains revealed that D. pigrum has a
small genome (average 1.86 Mb) and multiple predicted auxotrophies consistent with D. pigrum relying
on its human host and on cocolonizing bacteria for key nutrients. Further, the accessory genome of
D. pigrum harbored a diverse repertoire of biosynthetic gene clusters, some of which may have a role
in microbe-microbe interactions. These new insights into D. pigrum’s functions advance the field from
compositional analysis to genomic and phenotypic experimentation on a potentially beneficial bacterial
resident of the human upper respiratory tract and lay the foundation for future animal and clinical exper-
iments.IMPORTANCEStaphylococcus aureus and Streptococcus pneumoniae infections cause significant
morbidity and mortality in humans. For both, nasal colonization is a risk factor for infection. Studies
of nasal microbiota identify Dolosigranulum pigrum as a benign bacterium present when adults are free
of S. aureus or when children are free of S. pneumoniae Here, we validated these in vivo associations
with functional assays. We found that D. pigrum inhibited S. aureusin vitro and, together with a specific
nasal Corynebacterium species, also inhibited S. pneumoniae Furthermore, genomic analysis of D. pigrum
indicated that it must obtain key nutrients from other nasal bacteria or from humans. These phenotypic
interactions support the idea of a role for microbe-microbe interactions in shaping the composition of
human nasal microbiota and implicate D. pigrum as a mutualist of humans. These findings support the
feasibility of future development of microbe-targeted interventions to reshape nasal microbiota composi-
tion to exclude S. aureus and/or S. pneumoniae.
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ABSTRACT Multiple epidemiological studies identify Dolosigranulum pigrum as a
candidate beneficial bacterium based on its positive association with health, includ-
ing negative associations with nasal/nasopharyngeal colonization by the pathogenic
species Staphylococcus aureus and Streptococcus pneumoniae. Using a multipronged
approach to gain new insights into D. pigrum function, we observed phenotypic in-
teractions and predictions of genomic capacity that support the idea of a role for
microbe-microbe interactions involving D. pigrum in shaping the composition of hu-
man nasal microbiota. We identified in vivo community-level and in vitro phenotypic
cooperation by specific nasal Corynebacterium species. Also, D. pigrum inhibited S.
aureus growth in vitro, whereas robust inhibition of S. pneumoniae required both D.
pigrum and a nasal Corynebacterium together. D. pigrum L-lactic acid production was
insufficient to account for these inhibitions. Genomic analysis of 11 strains revealed
that D. pigrum has a small genome (average 1.86 Mb) and multiple predicted aux-
otrophies consistent with D. pigrum relying on its human host and on cocolonizing
bacteria for key nutrients. Further, the accessory genome of D. pigrum harbored a
diverse repertoire of biosynthetic gene clusters, some of which may have a role in
microbe-microbe interactions. These new insights into D. pigrum’s functions advance
the field from compositional analysis to genomic and phenotypic experimentation
on a potentially beneficial bacterial resident of the human upper respiratory tract
and lay the foundation for future animal and clinical experiments.
IMPORTANCE Staphylococcus aureus and Streptococcus pneumoniae infections cause
significant morbidity and mortality in humans. For both, nasal colonization is a risk
factor for infection. Studies of nasal microbiota identify Dolosigranulum pigrum as a
benign bacterium present when adults are free of S. aureus or when children are
free of S. pneumoniae. Here, we validated these in vivo associations with functional
assays. We found that D. pigrum inhibited S. aureus in vitro and, together with a spe-
cific nasal Corynebacterium species, also inhibited S. pneumoniae. Furthermore,
genomic analysis of D. pigrum indicated that it must obtain key nutrients from
other nasal bacteria or from humans. These phenotypic interactions support the
idea of a role for microbe-microbe interactions in shaping the composition of
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human nasal microbiota and implicate D. pigrum as a mutualist of humans.
These findings support the feasibility of future development of microbe-targeted
interventions to reshape nasal microbiota composition to exclude S. aureus
and/or S. pneumoniae.
KEYWORDS Dolosigranulum pigrum, Corynebacterium, Staphylococcus aureus,
Streptococcus pneumoniae, microbe-microbe interactions, interspecies interactions,
upper respiratory tract, nasal, microbiota, comparative genomics
Colonization of the human nasal passages by Staphylococcus aureus or Streptococcuspneumoniae is a major risk factor for infection by the colonizing bacterium at a
distant body site (1–5). Interventions that reduce the prevalence of colonization also
reduce the risk of infection and transmission (6, 7). S. aureus and S. pneumoniae are
major human pathogens that cause significant morbidity and mortality worldwide
(8–11). There are also concerns regarding rising rates of antimicrobial resistance (12)
and the potential for long-term effects of antibiotics early in life (13). Thus, efforts have
recently focused on the identification of candidate bacteria that confer colonization
resistance against S. aureus (14–21) and S. pneumoniae (22–25), with particular urgency
for S. aureus in the absence of an effective vaccine.
Dolosigranulum pigrum has emerged in multiple studies of the human upper
respiratory tract (URT) microbiota, colonizing with or without Corynebacterium species,
as potentially beneficial and/or protective against colonization by S. aureus and S.
pneumoniae (26–53) (reviewed in references 14, 54, 55, 56, and 57). However, little is
known about this Gram-positive, catalase-negative, Firmicute bacterium, first described
in 1993 (58). Microbiota studies sampling either nostrils or nasopharynx have shown
very similar results; therefore, for simplicity, we use “nasal” or “nasal passages” to
denote the area inclusive of the nostrils through the nasopharynx. D. pigrum and S.
aureus are inversely correlated in adult nasal microbiota (30, 41, 59), whereas, in
pediatric nasal microbiota, D. pigrum and members of the genus Corynebacterium are
overrepresented when S. pneumoniae is absent (26, 33). Moreover, children with D.
pigrum colonization of the nasal passages are less likely to have acute otitis media (27,
40) and it has been speculated that D. pigrum-dominated microbiota profiles might be
more resistant to invasive pneumococcal disease (46). Furthermore, D. pigrum abun-
dance in the nasal passages is inversely associated with wheezing and respiratory tract
infections in infants (28) and an abundance of D. pigrum with Corynebacterium in adults
provides greater community stability in the face of pneumococcal exposure (51). The
intriguing inference from these studies that D. pigrum plays a beneficial role in human
nasal microbiota deserves further investigation.
In contrast to the data mentioned above, there are very few reports of D. pigrum in
association with human disease (60–68). Its frequent identification in human nasal
microbiota (26–53, 69–81) and its rare association with infection are consistent with D.
pigrum functioning as a commensal and, possibly, as a mutualist of humans––charac-
teristics that support the idea of its potential for future use as a therapeutic. However,
its metabolism and its interplay with other nasal bacteria remain uncharted territory.
Using a multipronged approach, we have made significant advances in these areas.
First, we identified specific species of candidate bacterial interactors with D. pigrum by
analyzing nasal microbiota data sets from adults and children. Second, we used in vitro
phenotypic assays to show that D. pigrum exhibits distinct interaction phenotypes with
nasal Corynebacterium species, S. aureus, and S. pneumoniae. Third, on the basis of the
genomes of 11 distinct D. pigrum strains, we identify key predicted functions and
auxotrophies in its core genome plus a diversity of predicted biosynthetic gene clusters
(BCGs) in its accessory genome. This critical shift to phenotypic and genomic experi-
mentation marks a significant advance in understanding D. pigrum, a potentially
beneficial member of human nasal microbiota.
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RESULTS
Individual bacterial species are associated with D. pigrum in the nasal micro-
biota of both adults and children. D. pigrum is the only member of its genus, and
multiple 16S rRNA gene-based nasal microbiota studies have identified associations
between Dolosigranulum and other genera, such as Corynebacterium (see, e.g., refer-
ences 28, 29, 31, 36, 38, 40, 41, 43, and 82). In most cases, the taxonomic resolution in
the aforementioned studies was limited to the genus or higher taxonomic levels. Thus,
we sought to achieve finer taxonomic resolution and to determine which species are
associated with D. pigrum. We identified two nostril data sets with V1-V2/V1-V3 16S
rRNA gene sequences, regions that contain sufficient information for species-level
taxonomic assignment of most nose-associated bacteria (26, 41). After parsing se-
quences into species-level phylotypes, we interrogated each data set using analysis of
composition of microbiomes (ANCOM) (83) to identify bacterial species that display
differential relative abundances in the absence or presence of D. pigrum sequences
(Fig. 1; see also Table S1 in the supplemental material). In the nostrils of 99 children
ages 6 to 78 months (26), Corynebacterium pseudodiphtheriticum exhibited increased
differential relative abundance in the presence of D. pigrum, i.e., was positively asso-
ciated with D. pigrum, as was Moraxella nonliquefaciens (Fig. 1A). In the nostrils of 210
adults from the Human Microbiome Project (HMP), three Corynebacterium species––
Corynebacteriu accolens, C. propinquum, and C. pseudodiphtheriticum––and an unre-
solved supraspecies of C. accolens-macginleyi-tuberculostearicum were positively asso-
ciated with D. pigrum (Fig. 1B, panels ii to v), whereas S. aureus was negatively
associated with D. pigrum (Fig. 1B, panel vi). The associations identified in composi-
tional microbiota data observed here and in prior studies (28, 29, 31, 36, 38, 40, 41, 43,
FIG 1 Individual nasal Corynebacterium species exhibit increased differential relative abundances in the
presence of D. pigrum in human nostril microbiota. We used ANCOM to compare the species/
supraspecies-level compositions of 16S rRNA gene nostril data sets from (A) 99 children ages 6 to
78 months and (B) 210 adults where D. pigrum was either absent (Dpi) or present (Dpi) on the basis
of 16S rRNA gene sequencing data. Plots show only the taxa identified as statistically significant
(sig  0.05) after correction for multiple testing within ANCOM. The dark bar represents the median;
lower and upper hinges correspond to the first and third quartiles. Each gray dot represents the value
for a sample, and multiple overlapping dots appear black. Dpi  Dolosigranulum pigrum, Cac  Coryne-
bacterium accolens, Caa/Cma/Ctu  supraspecies Corynebacterium accolens_macginleyi_tuberculosteari-
cum, Cpr  Corynebacterium propinquum, Cps  Corynebacterium pseudodiphtheriticum, Mno  Moraxella
nonliquefaciens. Only three species and one supraspecies of Corynebacterium from among the larger
number of Corynebacterium supraspecies/species present in each data set met the significance threshold.
Specifically, in the adult nostril data set, there were 21 species and 5 supraspecies groupings of
Corynebacterium in addition to the reads of Corynebacterium that were nonassigned (NA) at the species
level. These data were previously published (see Table S7 in reference 41). In the pediatric data set, there
were 16 species of Corynebacterium in addition to those that were nonassigned among the species-level
Corynebacterium reads (see Table S2). The Log relative abundance numerical data represented in this
figure are available in Table S1.
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82) led to testable hypotheses about possible direct microbe-microbe interactions
between D. pigrum and the specific nasal Corynebacterium species, as well as between
D. pigrum and S. aureus. Therefore, we used in vitro phenotypic assays to test our
hypotheses about direct microbe-microbe interactions.
Nasal Corynebacterium species can enhance the growth of D. pigrum in vitro.
We hypothesized that the strong positive association between D. pigrum and the nasal
passage-associated Corynebacterium species might be due to these Corynebacterium
species releasing metabolites that enhance the growth of D. pigrum. To test this, we
quantified D. pigrum growth yields on unconditioned agar medium compared to the
yields seen on cell-free agar medium conditioned by growth of C. pseudodiphtheriticum,
C. propinquum, or C. accolens (Fig. 2). Conditioning agar medium by prior growth of any
of these three nasal Corynebacterium species increased the yield (measured as CFU) of
two D. pigrum strains (CDC4709-98 and KPL1914) by 1 to 2 orders of magnitude
compared to growth on unconditioned agar medium (Fig. 2A and B). Additionally, one
strain of C. pseudodiphtheriticum (Fig. 2A) and the C. accolens strain (Fig. 2B) increased
the growth yield of D. pigrum CDC2949-98, a strain with a higher baseline growth yield.
The increases in D. pigrum growth yield on Corynebacterium cell-free conditioned agar
medium (CFCAM) might have resulted from increased growth rate or increased viability
or both and might be consistent with the nasal Corynebacterium species either remov-
ing a toxin from the medium or releasing a metabolite that enhances growth and/or
survival of D. pigrum.
In contrast to the increase in D. pigrum growth yield on C. pseudodiphtheriticum
CFCAM (Fig. 2A), there was no increase in C. pseudodiphtheriticum strain KPL1989
growth yield on D. pigrum CFCAM (Fig. 2C). Thus, this growth enhancement goes in one
direction from nasal Corynebacterium species to D. pigrum. This is consistent with
unilateral cooperation of nasal Corynebacterium species––C. pseudodiphtheriticum, C.
propinquum or C. accolens––with D. pigrum in the nostril microbiota and supports the
observed positive in vivo community-level relationships (Fig. 1).
The positive association between C. accolens and D. pigrum in adult nostril micro-
biota data sets indicates that in vivo positive interactions between C. accolens and D.
pigrum prevail (Fig. 1B, panel ii). However, in vitro, we observed either a positive or a
negative interaction between C. accolens and D. pigrum depending on the assay
conditions. C. accolens, unlike C. propinquum and C. pseudodiphtheriticum, is a fatty acid
auxotroph, and triolein, a model host epithelial-surface triacylglycerol, served as a
source of needed oleic acid in our assays. We observed increased D. pigrum growth
yield on a semipermeable membrane atop C. accolens CFCAM consisting of brain heart
infusion (BHI) agar supplemented with triolein (BHIT) (Fig. 2B). In contrast, D. pigrum
was inhibited when placed directly onto this same C. accolens CFCAM (Table 1). This
inhibition is reminiscent of our previous finding that the C. accolens triacylglycerol
lipase LipS1 hydrolyzes triacylglycerols, releasing free fatty acids that inhibit S. pneu-
moniae (33), and S. pneumoniae served as a positive control for the effect of C. accolens
in this assay (Table 1). Both D. pigrum and S. pneumoniae belong to the order
Lactobacillales, and we hypothesized that D. pigrum might be similarly susceptible to
free fatty acids such as the oleic acid that C. accolens releases from triolein. Indeed, we
observed that oleic acid inhibited D. pigrum when we challenged D. pigrum with oleic
acid using a disk diffusion assay with S. pneumoniae as a positive control (Table 2). We
also challenged D. pigrum with various concentrations of oleic acid spread onto plates
of BHI agar medium. Similarly to the membrane-mediated effect seen in the C. accolens
CFCAM experiment described above, we observed D. pigrum growth at higher con-
centrations of oleic acid when it was placed on a semipermeable membrane atop the
oleic acid-coated medium than when it was placed directly on the oleic acid-coated
medium (Table 3). This indicates that the membrane provided some protection from
inhibition by oleic acid. Overall, these in vitro data indicate that C. accolens can both
inhibit the growth of D. pigrum by releasing antibacterial-free fatty acids from host
triacylglycerols, such as oleic acid from triolein (Tables 1 and 2), and enhance the
growth of D. pigrum by releasing an as-yet-unidentified factor(s) (Fig. 2B). Collectively,
Brugger et al.
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FIG 2 D. pigrum growth yields increase on cell-free conditioned agar medium (CFCAM) from nasal
Corynebacterium species but not in reverse. (A and B) Growth yield of D. pigrum strains CDC2949-98,
CDC4709-98, and KPL1914 was quantified as the number of CFU grown on a polycarbonate membrane
placed on (A) cell-free conditioned BHI agar from C. propinquum (aqua green) or C. pseudodiphtheriticum
(dark and light green) or (B) cell-free conditioned BHI-triolein (BHIT) agar from C. accolens (blue) and
compared to growth on unconditioned BHI agar (dark gray) or unconditioned BHIT agar (light gray),
respectively. (C) Growth yield of C. pseudodiphtheriticum KPL1989 on CFCAM from D. pigrum strains
(orange) compared to unconditioned medium (white) was assessed similarly. BHIT was used for growth
of C. accolens since it is a fatty acid auxotroph and releases needed oleic acid from triolein. Precondi-
tioning strains were grown on a 0.2-m-pore-size, 47-mm-diameter polycarbonate membrane for 2 days
to generate CFCAM. After removal, we then placed a new membrane on the CFCAM onto which we
spread 100 l of target bacterial cells that had been resuspended to an OD600 of 0.50 in 1 PBS. After
2 days of growth, CFU were enumerated as described in Materials and Methods. CFU counts were
compared independently for each individual strain (A and B, n  5) or medium (C, n  4) using a
Wilcoxon rank sum test with Bonferroni correction for multiple comparisons to the unconditioned
medium. Dark bars represent medians, lower and upper hinges correspond to the first and third quartiles,
and outlier points are displayed individually. *, P  0.05; **, P  0.001. CSBA, citrated sheep blood agar.
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these results point to a complex set of molecular interactions between these two
species.
D. pigrum inhibits S. aureus growth. The ANCOM of the adult nostril microbiota
data set revealed a negative association between S. aureus and D. pigrum (Fig. 1B, panel
vi). Direct antagonism would be the simplest mechanism underpinning this observa-
tion. Therefore, we assayed for the effect of 10 different strains of D. pigrum on S.
aureus. We gave D. pigrum a head start to compensate for its lower growth rate in vitro.
S. aureus growth was inhibited when it was inoculated adjacent to a pregrown
inoculum of each of these 10 D. pigrum strains on agar medium (Fig. 3A). In contrast,
a pregrown inoculum of S. aureus did not inhibit D. pigrum (Fig. 3B). Furthermore,
comparing three representative D. pigrum strains, none of the D. pigrum strains, when
pregrown, inhibited the other D. pigrum strains (Fig. 3C).
D. pigrum production of lactic acid is unlikely to be the primary mechanism for
negative associations with S. pneumoniae or S. aureus. D. pigrum lactic acid pro-
duction has been proposed as a mechanism to explain epidemiologic observations of
negative associations between D. pigrum and S. pneumoniae (82). Under nutrient-rich
conditions in vitro, three tested strains of D. pigrum produced from 5.7 to 8.2 mM
L-lactic acid, with strain KPL1914 producing the highest concentration (Fig. 4A). There-
fore, we assayed for growth of S. pneumoniae in D. pigrum KPL1914 cell-free condi-
tioned medium (CFCM) and in BHI broth supplemented with various concentrations of
L-lactic acid. Three of the four S. pneumoniae strains tested showed some growth in
22 mM lactic acid (Fig. 4B), and all strains displayed more growth in BHI medium
supplemented with 11 mM L-lactic acid than in the D. pigrum KPL1914 CFCM, which had
7.5 mM D. pigrum-produced L-lactic acid (Fig. 4B). Furthermore, growth of S. pneu-
moniae alone under these conditions resulted in a higher concentration of L-lactic acid
than did D. pigrum growth (see Fig. S1 in the supplemental material). Thus, the
restriction of S. pneumoniae growth in D. pigrum CFCM is unlikely to have been due to
production of lactic acid by D. pigrum. More likely, it reflected competition for nutrients
since fresh medium was not added to the CFCM, which, therefore, would have a lower
concentration of sugars than BHI broth. However, the possibility of D. pigrum produc-
tion of a toxin and/or an antipneumococcal compound in BHI broth cannot be
excluded. We also tested the in vitro effect of L-lactic acid on two strains of S. aureus.
Both showed some growth in 33 mM lactic acid (Fig. 4C). Thus, D. pigrum did not
produce enough L-lactic acid to restrict S. aureus growth under the tested conditions.
TABLE 1 In contrast to growth on a semipermeable membrane, D. pigrum is inhibited
when grown directly on cell-free C. accolens-conditioned BHI agar supplemented with
triolein as a source of oleic acid
Conditioning strain







C. accolens KPL1818 0 0 0
C. propinquumT DSM44285 0  
C. pseudodiphtheriticum KPL1989   
a0, no growth; , growth detected, n  3.











20 10.3  4.7 12.0  2.9 17.0  2.1
50 22.0  5.4 26.8  4.4 28.4  7.0
100 26.3  6.7 35.8  4.5 39.4  5.0
aMean zone of inhibition (ZOI)  standard deviation (SD) produced in a disc diffusion assay. ZOIs were
measured as the smallest diameter of inhibited growth, and measurements included disc diameter (6 mm).
Results from biological replicates (n  4 for S. pneumoniae, n  5 for D. pigrum) were averaged.
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Furthermore, growth of S. aureus alone resulted in a concentration of L-lactic acid
similar to that seen with D. pigrum growth (Fig. S1). In contrast to the S. pneumoniae
results, we would not expect depletion of sugars to have a large effect on S. aureus
growth in D. pigrum CFCM given its ability to utilize a broader repertoire of energy
sources, e.g., amino acids. Indeed, both S. aureus strains showed only a minimal
decrease in growth in D. pigrum CFCM. This also revealed differences in D. pigrum
production of the anti-S. aureus activity during growth on BHI agar medium (Fig. 3)
versus growth in BHI broth (Fig. 4C). Levels of excretion of metabolites may differ
during growth in liquid versus on agar medium, and the mechanism of the D. pigrum
anti-S. aureus activity is yet to be identified.
D. pigrum and C. pseudodiphtheriticum inhibit S. pneumoniae growth together
but not alone. Since the effects seen with C. pseudodiphtheriticum were positively
associated with the presence of D. pigrum (Fig. 1), we investigated their combined
effects on S. pneumoniae growth. Agar medium conditioned with a coculture of C.
pseudodiphtheriticum strain KPL1989 and D. pigrum strain CDC4709-98 inhibited S.
pneumoniae growth, whereas agar medium conditioned with a monoculture of either
C. pseudodiphtheriticum or D. pigrum alone did not (Fig. 5; see also Fig. S2). This might
have been due to cocultivation resulting either in a greater level of nutrient competi-
tion than monoculture of either commensal alone or in the production of a diffusible
TABLE 3 A 0.2-m-pore-size, 47-mm-diameter polycarbonate membrane provides D.
pigrum with some protection against inhibition by oleic acid in vitroa
Plated vol of
oleic acid (g)
Result for indicated D. pigrum strain
Growth directly on agar Growth on membrane
KPL1914 CDC4709-98 KPL1914 CDC4709-98
500 0 0 0 
50 0 0  
5    
0.5    
0.05    
0 (BHI agar)    
0 (CSBA)    
a0, no growth; , growth detected; n  3. CSBA, citrated sheep blood agar.
FIG 3 Ten different strains of D. pigrum inhibit methicillin-resistant S. aureus USA300 strain JE2 whereas
S. aureus does not inhibit D. pigrum. (A) Ten pregrown D. pigrum isolates produced a diffusible activity
that inhibited the growth of S. aureus strain JE2. (B) When S. aureus was pregrown in this assay, there was
no visible inhibition of subsequently inoculated D. pigrum. (C) Similarly, we did not observe any inhibition
in a pairwise comparison of three representative strains of D. pigrum in this assay. All growth was on BHI
agar in the independent experiments (n  3) represented in panels A, B, and C. Representative images
are shown for each strain. The respective pregrown strain (D. pigrum or S. aureus) was resuspended in
PBS, and then a 5-l drop was placed on BHI agar and pregrown for 48 h (D. pigrum) or 24 h (S. aureus).
After that, the indicator strain was inoculated at a location adjacent to the pregrown strain. Inhibition was
assessed after 24 and 48 h (48-h results are shown here). For panels A and B, similar results were observed
using S. aureus Newman.
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compound(s) toxic/inhibitory to S. pneumoniae by either D. pigrum or C. pseudodiph-
theriticum or both D. pigrum and C. pseudodiphtheriticum when grown together. (Of
note, cocultivation of D. pigrum and C. pseudodiphtheriticum in liquid BHI medium did
not increase the level of L-lactic acid compared to growth of D. pigrum alone [Fig. S1].)
Along with the Corynebacterium species enhancement of D. pigrum growth yield (Fig. 2)
and the D. pigrum inhibition of S. aureus growth (Fig. 3), these data indicate that the
negative associations of D. pigrum with S. aureus and S. pneumoniae are likely mediated
by different molecular mechanisms.
To learn more about the functional capacity and genomic structure of D. pigrum, we
next turned to genomic analysis, which provided insights into some of the epidemio-
logic and phenotypic observations presented above.
The genomes of 11 D. pigrum strains reveal a small genome consistent with a
highly host-adapted bacterium. We analyzed one publicly available genome of D.
pigrum (ATCC 51524) and sequenced 10 additional strains (see Text S1 in the supple-
mental material), which were selected to ensure representation of distinct strains (see
Materials and Methods). To start, we focused on basic genomic characteristics. The 11
D. pigrum strain genomes had an average size of 1.86 Mb (median 1.88 Mb) with 1,693
predicted coding sequences (CDS) (see Tables A and B in Text S1). Approximately 1,200
CDS were core (see Fig. A and B and Table C in Text S1) and exhibited a high degree
of nucleotide and amino acid sequence conservation (see Fig. C in Text S1). As shown
in Text S1, we further analyzed synteny of two closed genomes (see Fig. D in Text S1)
and BLAST ring comparisons (see Fig. E in Text S1) and constructed a core-gene-based
phylogeny (see Fig. F in Text S1).
D. pigrum is a predicted auxotroph for amino acids, polyamines, and enzymatic
cofactors. The nasal environment is low in and/or lacking in key nutrients such as
methionine (84), and the small genome size (1.86 Mb) of D. pigrum is consistent with
reduced biosynthetic capacity. To gain insight into how D. pigrum functions in the nasal
FIG 4 Lactate production by D. pigrum is insufficient to inhibit pathobiont growth. Strains of S. pneumoniae and S. aureus grew in the presence
of higher levels of L-lactic acid than those produced by D. pigrum in vitro. (A) The concentration of L-lactic acid (mM) produced by three D. pigrum
strains was measured after 24 h of gentle shaken aerobic growth in BHI broth at 37°C (n  5) compared to the basal concentration of L-lactic acid
in BHI medium alone (none). (B) The average growth (OD600) of 4 S. pneumoniae strains in D. pigrum KPL1914 CFCM or in unconditioned BHI broth
supplemented with different concentrations of L-lactic acid measured after 19 to 20 h of static aerobic growth at 37°C (n  4). (C) The average
growth (OD600) of 2 S. aureus strains in D. pigrum KPL1914 CFCM or in unconditioned BHI broth supplemented with different concentrations of
L-lactic acid measured after 19 to 20 h of shaken aerobic growth at 37°C (n  4). In panels A and B, the average pH of the D. pigrum CFCM was
6.40 (0.06). The pH of BHI without lactic acid (0 mM) was adjusted to match the pH of the CFCM, to control for any effect of pH alone. Average
levels of growth of S. pneumoniae in CFCM and 11 mM L-lactic acid were analyzed independently for each individual strain using a Wilcoxon rank
sum test. Dark bars represent medians, lower and upper hinges correspond to the first and third quartiles, and outlier points are displayed
individually, except in panel A, where dots for all individual sample values are represented. *, none of the S. pneumoniae or S. aureus strains
displayed growth in 55 mM L-lactate.
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environment, we examined all 11 genomes, finding evidence of auxotrophy for some
amino acids (e.g., methionine), polyamines (e.g., putrescine and spermidine), and
enzymatic cofactors (e.g., biotin) across all strains. In turn, we identified putative
degradation pathways (e.g., methionine), transporter pathways (e.g., polyamines and
biotin), and salvage pathways (e.g., folate), suggesting that D. pigrum acquires some
required nutrients exogenously. Section I in Text S2 contains additional details plus
predictions of acquisition of metal cofactors. The auxotrophy predictions may be
incomplete, since we were unable to grow D. pigrum in a chemically defined medium
with all 20 amino acids that was putatively replete on the basis of these predictions.
Apparent auxotrophy for a number of required nutrients indicates that these must be
available either from the host or from neighboring microbes in human nasal passages,
e.g., possibly from nasal Corynebacterium species.
Whole-genome sequencing indicates that D. pigrum metabolizes carbohy-
drates to lactic acid via homofermentation. D. pigrum produced lactate during in
vitro cultivation (Fig. 4A). Lactic acid bacteria mainly perform either homofermentation
or heterofermentation of carbohydrates (85). Therefore, we examined the genomic
capacity of D. pigrum for carbohydrate metabolism (see section II in Text S2). D. pigrum
genomes lacked genes required for a complete tricarboxylic acid cycle, which is
consistent with fermentation. Moreover, we identified genes encoding a complete glyco-
lytic pathway in all 11 strains that are consistent with homofermentation. All 11 strains
harbored a predicted L-lactate dehydrogenase (EC 1.1.1.27) which catalyzes the reduction
of pyruvate to lactate, regenerating NAD for glycolysis (GAPDH [glyceraldehyde-3-
phosphate dehydrogenase] step), consistent with homofermentation to L-lactate as the
main product of glycolysis.
The accessory genome of 11 D. pigrum strains contains a diversity of biosyn-
thetic gene clusters predicted to encode antibiotics. Lactic acid production alone
appears insufficient to account for the negative in vitro associations of D. pigrum with
FIG 5 D. pigrum and C. pseudodiphtheriticum grown together but not D. pigrum alone inhibited S.
pneumoniae in an in vitro agar medium-based assay. Representative images are shown of S. pneumoniae
603 growth on (A) BHI medium alone or on CFCAM from (B) C. pseudodiphtheriticum KPL1989, (C) D.
pigrum KPL1914, or (D) both D. pigrum and C. pseudodiphtheriticum grown in a mixed inoculum (n  4).
To condition the medium, we cultivated D. pigrum and/or C. pseudodiphtheriticum on a membrane, which
was then removed prior to spreading a lawn of S. pneumoniae. For monoculture, 100 l of either D.
pigrum or C. pseudodiphtheriticum, resuspended to an OD600  0.50, were inoculated onto the mem-
brane. For mixed coculture, 50 l of D. pigrum (OD600  0.50) were mixed with 50 l of C. pseudodiph-
theriticum (OD600  0.50) to yield a final volume of 100 l for the inoculum, such that each bacterial
species was present in the coculture inoculum at half the amount used for the corresponding monocul-
ture inoculum. Images were cropped. Black marks indicate edges where the membrane had been.
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S. aureus and with S. pneumoniae (Fig. 4). To delve further into the genetic capacity of
D. pigrum for possible mechanisms of inhibition, we explored the accessory genome of
the 11 sequenced strains. Consistent with a prior report (60), D. pigrum appears to be
broadly susceptible to antibiotics (see section III in Text S2). What emerged in our
analysis was a diversity of biosynthetic gene clusters (BGCs) (see Table A and Fig. A in
Text S2), including a diversity of BGCs predicted to encode candidate antibiotics.
Strikingly, although 10 of 10 strains tested displayed inhibition of S. aureus growth in
vitro (Fig. 3), there was no single BGC common to all 10 strains that might encode a
compound with antibiotic activity. On the basis of these data, we hypothesize that D.
pigrum uses a diverse repertoire of BGCs to produce bioactive molecules that play key
roles in interspecies interactions with its microbial neighbors, e.g., for niche competi-
tion, and potentially with its host. This points to a new direction for future research on
the functions that underlie the positive associations of D. pigrum in human nasal
microbiota with health and highlights the need to develop a system for genetic
engineering of D. pigrum.
DISCUSSION
D. pigrum was shown to be associated with health in multiple genus-level compo-
sitional studies of human URT/nasal passage microbiota. In nasal passage microbiota
data sets, we identified positive associations of D. pigrum with specific species of
Corynebacterium in adults and children and a negative association of D. pigrum with S.
aureus in adults (Fig. 1). We observed phenotypic support for these associations. First,
unilateral cooperation from three common nasal Corynebacterium species enhanced D.
pigrum growth yields (Fig. 2). Second, D. pigrum inhibited S. aureus (Fig. 3). Our genomic
analysis revealed auxotrophies consistent with D. pigrum reliance on cocolonizing
microbes and/or the human host for key nutrients. Genomic analysis also showed an
aerotolerant anaerobe that performs homofermentation to lactate. However, D. pigrum
lactate production (Fig. 4A) was insufficient to inhibit either S. pneumoniae (Fig. 4B) or
S. aureus (Fig. 4C) and therefore is not the sole contributor to negative associations with
S. pneumoniae and S. aureus in vivo. Consistent with the reports of a negative associ-
ation between D. pigrum (usually in conjunction with Corynebacterium) and S. pneu-
moniae, we observed that cocultivation of D. pigrum and C. pseudodiphtheriticum
produced a diffusible activity that robustly inhibited S. pneumoniae (Fig. 5; see also
Fig. S2 in the supplemental material) whereas monoculture of either did not. Finally, we
uncovered a surprisingly diverse repertoire of BGCs in 11 D. pigrum strains, revealing
potential mechanisms for niche competition that were previously unrecognized. These
data mark a significant advance in the study of D. pigrum and set the stage for future
research on molecular mechanisms.
The in vitro interactions of D. pigrum with S. aureus and with S. pneumoniae
support inferences from composition-level microbiota data of competition between
D. pigrum and each pathobiont. However, these interactions differed in vitro. D.
pigrum alone inhibited S. aureus, but D. pigrum plus C. pseudodiphtheriticum,
together, robustly inhibited S. pneumoniae. These results point to a more complex
set of interactions among these specific bacterial members of the human nasal
microbiota which likely exists in the context of a network of both microbe-microbe
and microbe-host interactions. To date, mechanisms for only a few such interac-
tions have been described. For example, a C. accolens triacylglycerol lipase (LipS1)
releases antipneumococcal free fatty acids from model host surface triacyclglycerols
in vitro, pointing to habitat modification as a possible contributor to S. pneumoniae
colonization resistance (33).
Multiple mechanisms could result in D. pigrum inhibition of S. aureus in vitro,
including nutrient competition and excretion of a toxic primary metabolite or of an
anti-S. aureus secondary metabolite (i.e., an antibiotic). Initial bioassay-guided fraction-
ation approaches failed to identify such a mechanism. However, the data showing the
existence of diverse repertoires of BGCs among the 11 D. pigrum strains are intriguing
because they include predicted bacteriocins, including lanthipeptides. For example, 4
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of the 11 strains harbored putative type II lanthipeptide biosynthetic gene clusters.
These clusters are characterized by the presence of the LanM enzyme, containing both
dehydration and cyclization domains needed for lanthipeptide biosynthesis (86). Align-
ment of these enzymes with the enterococcal cytolysin LanM revealed conserved
catalytic residues in both domains (87). Cleavage of the leader portion of the lanthip-
eptide is necessary to produce an active compound, and the presence of peptidases
and transporters within these BGCs suggests that these D. pigrum strains might secrete
an active lanthipeptide, which could play a role in niche competition with other
microbes. Additionally, 8 of the 11 D. pigrum genomes examined contain putative
bacteriocins, or bactericidal proteins and peptides. Intriguingly, the D. pigrum strains
exhibiting the strongest inhibition of S. aureus (CDC4709-98, CDC39-95, and KPL1914)
(Fig. 3) were the only strains that contained both a lanthipeptide BGC and a bacteriocin,
further indicating that D. pigrum may employ multiple mechanisms to inhibit S. aureus
growth. Also, if both are required for the in vitro inhibition, this might explain the
negative results from bioassay-guided fractionation. Mechanisms are coming to light
that account for how other nasal bacteria interact with S. aureus. For example, com-
mensal Corynebacterium species excrete a yet-to-be-identified substance that inhibits S.
aureus autoinducing peptides blocking agr quorum sensing (QS), and shifting S. aureus
toward a commensal phenotype (88). Also, the yet-to-be-identified mechanism of C.
pseudodiphtheriticum contact-dependent inhibition of S. aureus is mediated through
phenol-soluble modulins, the expression of which increases during activation of agr QS
(89). Within broader Staphylococcus-Corynebacterium interactions, C. propinquum out-
competes coagulase-negative Staphylococcus, but not S. aureus, for iron in vitro using
the siderophore dehydroxynocardamine, the genes for which are transcribed in vivo in
human nostrils (90). Interphylum Actinobacteria-Firmicutes interactions also occur be-
tween Cutibacterium acnes and Staphylococcus species (reviewed in reference 14). For
example, some strains of C. acnes produce an antistaphylococcus thiopeptide, cutimy-
cin, in vivo and the presence of the cutimycin BGC is correlated with microbiota
composition at the level of the individual human hair follicle (91). Of note, Actinobac-
teria competition with coagulase-negative Staphylococcus species could also have
network-mediated (indirect) effects on S. aureus via the well-known competition
among Staphylococcus species (reviewed in reference 92), which can be mediated by,
e.g., antibiotic production (15–17, 19), interference with S. aureus agr QS (18, 20, 93, 94),
or extracellular protease activity (95), among other means (14). Further rounding out
the emerging complexity of microbe-microbe interactions in nasal microbiota, multiple
strains of Staphylococcus, particularly S. epidermidis, inhibit the in vitro growth of other
nasal and skin bacteria, including D. pigrum, via yet-to-be-identified mechanisms (16).
The evidence described above points to a wealth of opportunity to use human nasal
microbiota as a model system to learn how bacteria use competition to shape their
community.
Direct cooperation could contribute to the observed positive associations between
bacterial species in epidemiological microbiome studies. Conditioning medium with
any of the three nasal Corynebacterium species positively associated with D. pigrum in
vivo in human nasal microbiota (Fig. 1) enhanced the growth yield of some D. pigrum
strains (Fig. 2). This is possibly accounted for by excretion of a limiting nutrient or by
removal of a toxic medium component. The genomic predictions of auxotrophy might
favor nasal Corynebacterium species providing cooperation to D. pigrum by excretion of
a limiting nutrient. Indeed, mass spectrometry indicated that a number of nutrients are
limiting in the nose (84).
There were several limitations of our study. First, we analyzed the genomes of 11
strains that were primarily isolated in the setting of disease. It is unclear whether these
strains were contaminants or pathogenic contributors (60). However, D. pigrum strains
are infrequently associated with disease (61–68). These 11 D. pigrum strains did not
appear to encode potential virulence factors (see section III in Text S2 in the supple-
mental material), which is consistent with D. pigrum acting primarily as a mutualistic
species of humans. Second, the ongoing search for a fully defined chemical medium
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permissive for D. pigrum growth precluded experimental verification of predicted
auxotrophies and further investigation of how the presence of nasal Corynebacterium
enhances D. pigrum growth yields. Third, the D. pigrum anti-S. aureus factor has eluded
purification and identification efforts with standard chemistry approaches and D.
pigrum is not yet genetically tractable, limiting the use of genetic approaches to
identify it. Fourth, to date, there has been no animal model for nasal colonization with
D. pigrum and Corynebacterium species, which stymies direct in vivo testing of the
hypothesis of pathobiont inhibition and points to another area of need within the nasal
microbiome field.
In summary, we validated in vivo associations from human bacterial microbiota
studies with functional assays that support the hypothesis that D. pigrum is a mutualist
with respect to its human host, rather than a purely commensal bacterium. Further, the
data from these phenotypic interactions support the idea of a role for microbe-microbe
interactions in shaping the composition of human nasal microbiota and, thus, the
possibility of developing microbe-targeted interventions to reshape community com-
position. The next step will be to identify the molecular mechanisms of those interac-
tions and to assess their role in the human host. Such work could establish the premise
for future studies to investigate the therapeutic potential of D. pigrum as a topical nasal
probiotic for use in patients with recurrent infections with S. pneumoniae, possibly in
conjunction with a nasal Corynebacterium species, or with S. aureus, in conjunction with
established S. aureus decolonization techniques (96).
MATERIALS AND METHODS
Species-level reanalysis of a pediatric nostril microbiota data set. Laufer et al. analyzed nostril
swabs collected from 108 children ages 6 to 78 months (26). Of these, 44% were culture positive for S.
pneumoniae and 23% were diagnosed with otitis media. 16S rRNA gene V1-V2 sequences were generated
using Roche/454 with primers 27F and 338R. We obtained 184,685 sequences from the authors, of which
94% included sequence matching primer 338R and 1% included sequence matching primer 27F. We
performed demultiplexing in QIIME (97) (split_libraries.py), filtering reads for those 250 bp in length,
those with a quality score of 30, and those with barcode type hamming_8. Then, we eliminated
sequences from samples for which there were no metadata (n  108 for metadata), leaving 120,963
sequences on which we performed de novo chimera removal in QIIME (USEARCH 6.1) (98, 99), yielding
120,274 16S rRNA V1-V2 sequences. We then aligned the 120,274 chimera-cleaned reads in QIIIME
(PyNAST) (100), using eHOMDv15.04 (41) as a reference database, and trimmed the reads using
“o-trim-uninformative-columns-from-alignment” and “o-smart-trim” scripts (101). A total of 116,620 reads
(97% of the chimera-cleaned reads) were recovered after the alignment and trimming steps. After these
initial cleaning steps, we retained only the 99 samples with more than 250 reads. We analyzed these data
set of 99 samples with a total of 114,909 reads using MED (101) with minimum substantive abundance
of an oligotype (-M) equal to 4 and maximum variation allowed in each node (-V) equal to 6 nucleotides
(nt), which equals 1.6% of the 379-nucleotide length of the trimmed alignment. Of the 114,909
sequences, 82.8% (95,164) passed the -M and -V filtering and are represented in the MED output.
Oligotypes were assigned taxonomy in R with the dada2::assignTaxonomy() function (an implementation
of the naive Bayesian RDP classifier algorithm with a kmer size of 8 and a bootstrap value of 100) (102,
103) using the eHOMDv15.1 V1-V3 Training Set (version 1) (41) and a bootstrap value of 70. We then
collapsed oligotypes within the same species/supraspecies, yielding the data shown in Table S2 in the
supplemental material.
Microbiota community comparison (Fig. 1). The pediatric 16S rRNA gene V1-V2 data set analyzed
at the species level (Table S2) and the HMP adult 16S rRNA gene V1-V3 data set previously analyzed at
the species level (see Table S7 in reference 41) were used as input for the ANCOM, including all identified
taxa (i.e., we did not remove taxa with low relative abundance). ANCOM (version 1.1.3) was performed
using the presence or absence of D. pigrum, on the basis of the 16S rRNA gene sequencing data, as group
definer. ANCOM default parameters were used (sig  0.05, tau  0.02, theta  0.1, repeated  FALSE [i.e.,
Kruskal-Wallis test]), except that we performed a correction for multiple comparisons (multcorr  2)
instead of using the default no correction (multcorr  3) (83). The Log relative abundance values for the
taxa identified as statistically significant (sig  0.05) are represented in Fig. 1 and are also available in
Table S1.
Cultivation from frozen stocks. Bacterial strains (see Table A in Text S1 in the supplemental
material; see also Table S3) were cultivated as described here unless stated otherwise. Across the various
methods, strains were grown at 37°C with 5% CO2 unless otherwise noted. D. pigrum strains were
cultivated from frozen stocks on BBL Columbia colistin-nalidixic acid (CNA) agar with 5% sheep blood (BD
Diagnostics) for 2 days. Corynebacterium species were cultivated from frozen stocks on BHI agar (C.
pseudodiphtheriticum and C. propinquum) or on BHI agar supplemented with 1% Tween 80 (C. accolens)
for 1 day. The resuspensions described below were made by harvesting colonies from agar medium and
resuspending in 1 phosphate-buffered saline (PBS). Of note, we primarily use agar medium because in
our experience D. pigrum exhibits more consistent growth on agar medium than in liquid medium.
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Likewise, growth on a semisolid surface is likely to better represent growth on nasal surfaces than would
growth under the well-mixed conditions of shaking liquid medium.
Preconditioning growth yield assays (Fig. 2). To assess the growth yield of D. pigrum on a
polycarbonate membrane atop media conditioned by Corynebacterium spp., each Corynebacterium strain
was resuspended from growth on agar medium to an optical density at 600 nm (OD600) of 0.50 in 1 PBS.
Then, 100 l volumes of each resuspension were individually spread onto a 0.2-m-pore-size, 47-mm-
diameter polycarbonate membrane (EMD Millipore, Billerica, MA) atop 20 ml of either BHI agar for C.
pseudodiphtheriticum and C. propinquum or BHI agar supplemented with triolein (BHIT) (CAS catalog no.
122-32-7, Acros) spread atop the agar medium, as previously described (33), for C. accolens. After 2 days
of growth, the membranes with Corynebacterium cells were removed, leaving CFCAM. On each plate of
CFCAM, we placed a new membrane onto which we spread 100 l of D. pigrum cells that had been
resuspended to an OD600 of 0.50 in 1 PBS. After 2 days, the membranes with D. pigrum were removed,
placed in 3 ml 1 PBS, and subjected to vortex mixing for 1 min to resuspend cells. Resuspensions were
diluted 1:10 six times, dilutions were inoculated onto BBL CNA agar with 5% sheep blood, and CFU were
enumerated after 2 to 3 days of growth. To assess the growth yield of C. pseudodiphtheriticum on a
polycarbonate membrane atop media conditioned by D. pigrum, strains KPL1914 and CDC4709-98 were
grown for 2 days as described above. C. pseudodiphtheriticum KPL1989 growth yield was then measured
as described above.
Growth of D. pigrum directly on BHI agar medium supplemented with triolein and conditioned
by growth of nasal Corynebacterium species (Table 1). Onto BHI agar supplemented with 200 U/ml
of bovine liver catalase (C40-500MG, Sigma) (BHIC), we spread 50 l of 100 mg/ml of triolein (BHICT). We
then spread 50 l of a resuspension (OD600 of 0.50) of each Corynebacterium strain onto a 0.2-m-pore-
size, 47-mm-diameter polycarbonate membrane placed atop 10 ml of BHICT agar in a 100-mm-by-15-mm
petri dish. After 2 days, we removed each membrane with Corynebacterium cells, leaving CFCAM. Using
a sterile cotton swab, we then spread a lawn of either D. pigrum (from cells resuspended to an OD600 of
0.50 in 1 PBS) or S. pneumoniae (taken directly from agar medium) onto the CFCAM. Each lawn was
then grown for 1 to 2 days before documentation of growth or inhibition of growth was performed with
digital photography.
Oleic acid disc diffusion assay (Table 2). A lawn of D. pigrum or S. pneumoniae was spread onto
10 ml of BHIC agar using a sterile cotton swab as described above. Oleic acid (Sigma-Aldrich) was
dissolved to reach final concentrations of 2 mg/ml, 5 mg/ml, and 10 mg/ml in ethanol, and then we
added 10 l of each to separate, sterile 0.2-m-pore-size, 6-mm-diameter filter discs (Whatman), with
10 l of ethanol alone added to a disc as a control. After the solvent was allowed to evaporate, filter discs
were placed on the bacterial lawns, which were then allowed to grow for 1 day before measurement of
zones of inhibition and photography were performed.
Growth of D. pigrum directly on versus atop a membrane on oleic acid-coated agar medium
(Table 3). Oleic acid was dissolved in 100% ethanol to a concentration of 5 mg/ml and then further
diluted 10-fold 5 times in ethanol. For each dilution, 100 l was spread on a separate plate of BHI agar
medium. Next, 10 l of D. pigrum KPL1914 and CDC4709-98, each resuspended to an OD600  0.3, were
inoculated both directly onto the oleic acid-coated agar medium and atop of a 0.2-m-pore-size,
47-mm-diameter polycarbonate membrane (EMD Millipore, Billerica, MA) on the same plate. After the
plates had been maintained for 2 days at 37°C, we assessed and photographed the growth. In addition,
for each dilution and strain, one spot on the membrane was resuspended in PBS to assess CFU counts
after serial dilutions and plating on blood agar plates (see above).
D. pigrum-S. aureus side-by-side coculture assays (Fig. 3). D. pigrum cells were grown from frozen
stocks as described above. S. aureus JE2 was grown overnight on BBL Columbia CNA agar with 5% sheep
blood. Bacterial cells were harvested with sterile cotton swabs and resuspended in sterile 1 PBS to a
minimal OD600 of 0.3 for D. pigrum and 0.1 for S. aureus. Next, 5-l drops were individually inoculated on
BHI agar medium and incubated for 2 days for D. pigrum and 1 day for S. aureus. Then, 5-l drops of
resuspended bacteria to be screened for inhibition were inoculated at different distances from the
pregrown bacteria. Inhibition was assessed daily and photographically documented.
Measurement of L-lactic acid concentration (Fig. 4A). S. pneumoniae, S. aureus, C. pseudodiphthe-
riticum, and D. pigrum cells were grown from frozen stocks as described above. Cells were then harvested
with a sterile cotton swab, resuspended to an OD600 of 0.50 in 1 PBS, and inoculated at 1:25 into BHI
broth for overnight growth with gently shaking (50 to 60 rpm) at 37°C under atmospheric conditions.
For mixed subcultures, i.e., C. pseudodiphtheriticum and D. pigrum, a 1:1 mixture was inoculated at 1:25
into fresh BHI broth. The overnight culture was then inoculated at 1:25 into fresh BHI broth and grown
for 24 h at 37°C prior to measurement of the lactic acid concentration (mmol/liter) using a D-lactic
acid/L-lactic acid kit (catalog no. 11112821035, R-Biopharm AG) per the instructions of the manufacturer
and BHI as a negative control.
Growth of S. aureus and S. pneumoniae in D. pigrum cell-free conditioned liquid medium (CFCM
in Fig. 4B and C). After growth in BHI, as described for L-lactic acid measurement, the D. pigrum KPL1914
cells were removed with a 0.22-m-pore-size sterile filter, yielding cell-free conditioned medium (CFCM).
Each of S. aureus strains Newman and JE2 and S. pneumoniae strains TIGR4, DBL5, 603, and WU2 was
grown on BBL Columbia CNA agar with 5% sheep blood for 1 day, harvested with a sterile cotton swab,
resuspended to an OD600 of 0.30 in 1 PBS, inoculated at 1:100 into both D. pigrum CFCM and BHI broth,
and grown for 19 to 20 h at 37°C in shaking (S. aureus; 50 rpm) or static (S. pneumoniae) culture under
atmospheric conditions. Growth yield was quantified as OD600 absorbance.
Growth of S. aureus and S. pneumoniae in BHI broth supplemented with L-lactic acid (see lactic
acid data in Fig. 4B and C). Strains of S. aureus and S. pneumoniae were grown and harvested as
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described above for inoculation. BHI broth, supplemented with L-lactic acid (CAS no. 79-33-4; Fisher
BioReagents) at various concentrations from 11mM to 55 mM, was sterilized through a 0.22-m-pore-
size filter. After inoculation of each strain separately into BHI broth with L-lactic acid, cultures were grown
as described above for growth in CFCM. Growth yield was quantified as OD600 absorbance.
Growth assay for S. pneumoniae on BHI agar medium conditioned by monoculture versus
coculture of D. pigrum and/or C. pseudodiphtheriticum (Fig. 5; see also Fig. S2 in the supplemental
material). D. pigrum and C. pseudodiphtheriticum strains were grown from freezer stocks as described
above. Cells were harvested with sterile cotton swabs and resuspended in sterile PBS to an OD600 of 0.5.
We then spotted 100 l of 1:1 mixed resuspension on a polycarbonate membrane (see above) on BHI
agar medium containing 400 U/ml bovine liver catalase. After 2 days of growth, the polycarbonate
membrane with D. pigrum and/or C. pseudodiphtheriticum was removed from each plate, leaving CFCAM.
S. pneumoniae 603 (104) was grown overnight on BBL Columbia CNA agar with 5% sheep blood as
described above, and, using a sterile cotton swab, a lawn was streaked onto the CFCAM and allowed to
grow for 24 h. Growth/inhibition was assessed daily and photographically recorded. Imaging was difficult
due to the transparency of S. pneumoniae lawns.
Statistical analyses. R version 3.6.2 was used for statistical analysis and data visualization. The
Wilcoxon rank sum test (equivalent to the Mann-Whitney test) was performed using wilcox.test() with
paired  FALSE, alternative  ”two.sided”.
Ethics approval and consent to participate. We isolated D. pigrum KPL1914 and C. pseudodiph-
theriticum KPL1989 from the nostril of an adult as part of a protocol to study the bacterial microbiota
of the nostrils of healthy adults that was initially approved by the Harvard Medical School
Committee on Human Studies (105) and subsequently approved by the Forsyth Institute Institutional
Review Board.
Data availability.We declare that all data that support the findings of this study are available within
the paper (and its supplemental material); from publicly available repositories, i.e., GenBank (BioProject
accession numbers PRJNA379818 and PRJNA379966); or from the corresponding authors upon reason-
able request. All computer code for published tools used in this work is referenced in Materials and
Methods; custom-made code (i.e., loop code) is described in Materials and Methods. Further details are
available from the corresponding authors on reasonable request.
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